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Objective: To evaluate the epidemiology of candidiasis and the antifungal susceptibility
proﬁle of Candida species isolated from the intensive care unit (ICU) patients.
Methods: The study used a qualitative descriptive design. Relevant samples depending
on organ system involvement from 100 ICU patients were collected and processed.
Identiﬁcation and speciation of the isolates was conducted by the biochemical tests.
Antifungal susceptibility testing was carried out as per CLSI-M27-A3 document.
Results: Ninety Candida isolates were isolated from the different clinical samples: urine
(43.3%), tracheal aspirate (31.1%), urinary catheter (12.2%), endotracheal tube (7.8%),
abdominal drains (3.3%), sputum (2.2%). The incidence of candidiasis caused by non-
albicans Candida (NAC) species (63.3%) was higher than Candida albicans (36.7%).
The various NAC species were isolated as: Candida tropicalis (41.1%), Candida glab-
rata (10%), Candida parapsilosis (6.7%), Candida krusei (3.3%) and Candida kefyr
(2.2%). The overall isolation rate of Candida species from samples was 53.3%. Anti-
fungal susceptibility indicated that 37.8% and 7.8% of the Candida isolates were resistant
to ﬂuconazole and amphotericin B, respectively.
Conclusions: Predominance of NAC species in ICU patients along with the increasing
resistance being recorded to ﬂuconazole which has a major bearing on the morbidity and
management of these patients and needs to be further worked upon.1. Introduction
Nosocomial infections constitute a serious public health
problem and are among the major causes of morbidity andmortality leading to increased hospitalization time and conse-
quently, generating high costs for patient treatment [1]. In the
recent years, the incidence of nosocomial candidiasis has
increased throughout the world, starting from tertiary care
centers and spreading to community hospitals [2]. The
epidemiological surveillance program in the United States has
shown that 5%–10% of patients who admitted in the hospitals
acquire nosocomial infection. Of these, about 80% of fungal
infections were caused by Candida species. According to
studies by Centers for Disease Control, Candida albicans
(C. albicans) is the sixth most common cause of nosocomial
infections [1].
The frequent use of broad-spectrum antibiotics, central
venous catheters, urinary catheters, prosthetic devices and
abdominal surgery in intensive care unit (ICU) patients requiring
emergency care [3], put patients at a high risk of infection with
Candida species [4]. Furthermore, ICU admission itself hasarticle under the CC BY-NC-ND license (http://
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Candida species infection [5]. The most common species
implicated was C. albicans recently, when the incidence of
non-albicans Candida species (NAC) has risen dramatically
[6]. In recent decades, several countries around the world have
witnessed a change in the epidemiology of Candida infections,
characterized by a progressive shift from a predominance of
C. albicans to NAC species [7].
A worrisome trend is the increasing number of reports of
ﬂuconazole resistance among species that are typically
ﬂuconazole-susceptible, such as C. albicans. There are
several reports regarding this phenomenon, but larger epide-
miologic studies have failed to show a deﬁnite geographic or
temporal trend toward ﬂuconazole resistance, despite of
heavy azoles usage. This epidemiologic shift has greatly
impacted the therapeutic choices for initial and deﬁnite ther-
apy for this disease [8]. Since there is scanty data on
candidiasis in North India, the main objective of present
study was to perform a study on the epidemiology of
candidiasis and evaluate the antifungal susceptibility proﬁle
of the Candida species isolated from the ICU patients at
our tertiary care hospital.2. Materials and methods
2.1. Design and setting
A prospective study was focused on epidemiology of
candidiasis in ICU patients and to evaluate the antifungal sus-
ceptibility proﬁle of Candida species isolated from the ICU
patients. Relevant samples depending on organ system
involvement were collected from the ICU patients of a 1 500
bedded tertiary care hospital and processed in the Department of
Microbiology in an Indian medical college.Figure 1. Distribution of Candida spp. in different samples (n = 90).2.2. Ethics approval
Ethics committee approval was granted by the Institutional
Ethics Committee of the College & Associated Hospitals, India.
Written consent was taken from the patients and they were
informed that their participation was voluntary and that they
withdraw from the study at any stagewithout incurring any penalty.
2.3. Participants
All hospitalized medical/post-operative patients admitted to
ICU for > 48 h undergoing therapy for one or more acute organ
system failure or requiring intensive post-operative monitoring
was studied. Detailed clinical history and investigations of each
patient was recorded prospectively and analyzed.
2.4. Collection of samples
Relevant clinical samples depending on organ system
involvement were collected as: urine, sputum, tracheal aspirate,
urinary catheter, endotracheal tube, abdominal drains. All sam-
ples were inoculated on Sabouraud dextrose agar slants con-
taining gentamicin (0.02 mg/mL) and cycloheximide (0.5%).
One set of inoculated slants was incubated at 25 C and the other
at 37 C, and they were examined every other day for growth up
to 4–6 weeks.2.5. Microscopy, culture and identiﬁcation
Identiﬁcation and speciation of the isolates were done by
colony morphology, Gram's staining, germ tube formation, corn
meal agar with Tween 80, HiCrome Candida agar and enzy-
matic triphenyltetrazolium chloride reduction test. For further
characterization each isolate was subjected to carbohydrate
assimilation and fermentation tests as per standard recom-
mended procedures [9].
2.6. Antifungal susceptibility test
The in vitro minimal inhibitory concentrations (MICs) of the
ﬂuconazole and amphotericin B was done by the broth micro-
dilution method as per Clinical and Laboratory Standards Insti-
tute (CLSI) M27-A3 document using Roswell Park Memorial
Institute medium and 3-(N-morpholino) propane sulfonic acid
buffer. The concentration ranges tested were 0.125–128.000 mg/
mL for ﬂuconazole and 0.016–16.000 mg/mL for amphotericin
B. Candida parapsilosis (ATCC 22019) (C. parapsilosis) and
Candida krusei (ATCC 6258) (C. krusei) from the American
Type Culture Collection (ATCC) used as quality control with
each batch of clinical isolates [10]. The MIC breakpoints
recommended by CLSI guidelines were followed [10]. For
ﬂuconazole, MIC breakpoints were as follows: sensitive (MIC
8 mg/mL); susceptible-dose dependent (MIC 16–32 mg/mL);
resistant (MIC  64 mg/mL). For amphotericin B, isolates with
MICs of 1 mg/mL were categorized as resistant [10].3. Results
The age (mean ± SD) of the patients was 37.90 ± 17.20 years
(range 8–81 years). Candida colonization was seen in 57.3%
patients, with 90 Candida isolates from different samples
(Figure 1).
The majority of patients (77%) had one or more risk factors
at the time of the diagnosis of candidiasis (Table 1). The mean
age of patients with candidiasis (case group) was higher than
the patients admitted to the same ICU with no candidiasis
(control group). Case group was divided into two sub-groups:
ﬁrst (CG1) – patients with C. albicans colonization and sec-
ond (CG2) – patients with NAC colonization. The time of
hospital stay (mean) in CG2 (19.5 days) > CG1 (9.8
days) > controls (6.3 days) with no statistically signiﬁcant
difference. In control, CG1 and CG2 group, the percentage of
patients with an indwelling device and prolonged antibiotic
therapy was signiﬁcantly higher than control and CG1 group
Table 1
Risk factors for candidiasis among the ICU patients.
Variables Controlsa
(n = 50)
CG1 (n = 19) P value CG2 (n = 31) P value
Continuous variables (mean ± SD) Age (years) 34.50 ± 17.76 40.00 ± 17.76 0.86 36.60 ± 16.87 0.66
Length of hospital stay (days) 6.30 ± 2.83 9.80 ± 4.79 0.95 19.50 ± 31.83 0.76
Categorical variables
[n (%)]
Surgery (n = 47) 18 (36.0) 10 (52.6) 0.32 19 (61.3) 0.04*
Trauma (n = 14) 5 (10.0) 4 (21.1) 0.41 5 (16.1) 0.64
Pneumonia (n = 12) 4 (8.0) 1 (5.3) 0.69 7 (22.3) 0.12
Neurological (n = 9) 4 (8.0) 2 (10.5) 0.73 3 (9.7) 0.79
Malignancy (n = 6) 1 (2.0) 2 (10.5) 0.37 3 (9.7) 0.30
Tuberculosis (n = 9) 2 (4.0) 1 (5.3) 0.31 6 (19.4) 0.06
Renal failure (n = 4) 1 (2.0) 1 (5.3) 0.47 2 (6.5) 0.67
Heart disease (n = 5) 3 (6.0) 1 (5.3) 0.90 1 (3.2) 0.97
Anemia (n = 4) 2 (4.0) 0 (0.0) NA 0 (0.0) NA
Peritonitis (n = 16) 4 (8.0) 5 (26.3) 0.10 7 (22.3) 0.12
Multiple organ system
involvement (n = 17)
2 (4.0) 4 (21.1) 0.07 11 (35.5) 0.0006*
Indwelling devices (n = 77) 28 (56.0) 19 (100) NA 30 (96.8) 0.0002*
Prolonged antibiotic therapy (n = 55) 23 (46.0) 8 (42.1) 0.98 24 (77.4) 0.01*
Duration of stay > 1 week (n = 25) 4 (8.0) 7 (36.8) 0.01* 14 (45.2) 0.0003*
Immunosuppressant (n = 20) 2 (4.0) 6 (31.6) 0.005* 12 (38.7) 0.0002*
Diabetes mellitus (n = 21) 5 (10.0) 5 (26.3) 0.18 11 (35.5) 0.01*
Smoking (n = 12) 6 (12.0) 2 (10.5) 0.86 4 (12.9) 0.90
Previous surgery (n = 11) 6 (12.0) 1 (5.3) 0.70 4 (12.9) 0.90
*: Indication of signiﬁcant P values (P < 0.05); NA: Not applicable.
a: Patients admitted to the same ICU with no candidiasis; CG1: Patients with C. albicans infection; CG2: Patients with NAC infection.
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(Table 1).
Among the isolates, C. albicans accounted for 36.7% and
NAC species for 63.3% of all the Candida colonization cases.
Among the 63.3% NAC species isolates, the most common was
Candida tropicalis (C. tropicalis) (41.1%) followed by Candida
glabrata (C. glabrata) (10%), C. parapsilosis (6.7%), C. krusei
(3.3%) and Candida kefyr (C. kefyr) (2.2%).
Predominance of C. albicans was seen in urine (16.7%)
followed by tracheal aspirate (14.4%), catheter (3.3%), endo-
tracheal and abdominal drains (1.1% in each). NAC was alsoTable 2
Age wise distribution of patients and Candida species isolated from the pati
Age group (years) Total patients
(n)
Colonized patients
[n (%)]
Coloni
0–10 3 2 (4)
11–20 19 7 (14)
21–30 26 12 (24)
31–40 22 12 (24)
41–50 8 6 (12)
51–60 13 6 (12)
> 60 9 5 (10)
Total 100 50 (100)
Table 3
Susceptibility to ﬂuconazole and amphotericin B of colonized isolates of Ca
Isolates (number) Urine Sputum Cath
FLU AMB FLU AMB FLU
C. albicans (n = 33) 6 (40.0) 2 (13.3) 0 (0.0) 0 (0.0) 2 (66.6)
C. tropicalis (n = 37) 5 (35.7) 1 (7.1) 0 (0.0) 0 (0.0) 3 (42.8)
C. krusei (n = 3) 2 (100.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0)
C. parapsilosis (n = 6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
C. kefyr (n = 2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
C. glabrata (n = 9) 2 (40.0) 0 (0.0) 1 (50.0) 0 (0.0) 0 (0.0)
Total (n = 90) 15 (38.5) 4 (10.2) 1 (50.0) 0 (0.0) 5 (45.5)
FLU: Fluconazole drug, for ﬂuconazole, isolates with MICs of 64 mg/mL we
B, isolates with MICs of 1 mg/mL were categorized as resistant.predominant in urine (26.7%) followed by tracheal aspirate
(16.7%), catheter (8.9%), endotracheal (6.7%) and sputum
(2.2%). Among NAC spp.: C. tropicalis (15.6%), C. glabrata
(5.6%) and C. krusei (2.2%) were dominant in urine samples
while C. parapsilosis (2.2%) and C. kefyr (1.1%) were pre-
dominant in urine and tracheal aspirate samples.
Candida colonization rate was highest in 41–50 years
(75%) age group, followed by 0–10 years (66.67%), > 60
years (55.6%), 31–40 years (54.5%), 21–30 years (46.2%),
51–60 years (46.2%) and 11–20 years (36.8%) age group
(Table 2).ents.
zation rate (%) C. albicans
[n (%)]
NAC species
[n (%)]
Total isolates
[n (%)]
66.7 0 (0.0) 3 (3.3) 3 (3.3)
36.8 6 (6.6) 7 (7.7) 13 (14.5)
46.2 7 (7.8) 15 (16.6) 22 (24.5)
54.5 8 (8.9) 12 (13.3) 20 (22.2)
75.0 1 (1.1) 9 (10.0) 10 (11.1)
46.2 5 (5.7) 6 (6.7) 11 (12.2)
55.6 6 (6.6) 5 (5.7) 11 (12.2)
– 33 (36.7) 57 (63.3) 90 (100.0)
ndida species. n (%).
eter Endotracheal Tracheal Abdominal drains
AMB FLU AMB FLU AMB FLU AMB
0 (0.0) 0 (0.0) 0 (0.0) 4 (30.8) 0 (0.0) 0 (0.0) 0 (0.0)
0 (0.0) 3 (60.0) 1 (20.0) 3 (30.0) 1 (10.0) 1 (100.0) 0 (0.0)
0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0) 0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
0 (0.0) 3 (42.8) 1 (14.3) 8 (28.6) 2 (7.1) 2 (66.6) 0 (0.0)
re categorized as resistant; AMB: Amphotericin B drug, for amphotericin
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isolates (37.8%) were resistant to ﬂuconazole. Out of the 34
resistant Candida isolates, 12 (35.3%) were C. albicans and 22
(64.7%) were NAC species as: C. tropicalis 15 (68.2%),
C. krusei and C. glabrata 3 (13.6%) each and C. parapsilosis 1
(4.5%). However, 7 (7.8%) Candida isolates showed resistance
to amphotericin B; 2 (28.6%) were C. albicans and 5 (71.4%)
were NAC species as: C. tropicalis 3 (60%), C. krusei 2 (40%)
as shown in Table 3.
4. Discussion
In recent years, there had been a remarkable increase in the
use of indwelling devices in hospitals. Candida species are
important nosocomial pathogens. Modern medical procedures
including implantation of various kinds of devices contribute to
the risk factors for developing candidiasis [11].
In present study, the majority of patients (77%) had one or
more risk factors at the time of the diagnosis of candidiasis. The
most common risk factors in these patients were indwelling
devices accounting for 98%, followed by prolonged antibiotic
therapy (64%), surgery (58%), duration of stay > 1 week (42%),
immunosuppressants use (36%), diabetes mellitus (32%), mul-
tiple organ system involvement (30%), peritonitis and trauma
(18%) each, pneumonia (16%), tuberculosis (14%), smoking
(12%), previous surgery, neurological involvement and malig-
nancy (10%) each, renal failure (6%), heart disease (4%) of
patients with Candida colonization.
However, a study at USA reported that the presence of prior
intravenous antibiotics (95.8%), prior surgical procedure
(73.9%), diabetes mellitus (37.3%), cancer (21.1%), alcoholism
(16.9%), neutropenia (0.7%), renal failure (6.3%), corticosteroid
therapy (5.6%), parenteral nutrition (9.2%) were the common
risk factors in adult intensive care patients [12]. According to
Arslankoylu et al. on symptomatic and asymptomatic
candidiasis in a pediatric ICU, reported the use of broad
spectrum antibiotics and parenteral nutrition were the most
common risk factors followed by central venous catheter
(96.8%), blood transfusion (96.8%), surgery (45.2%) and use
of corticosteroids (35.5%) [13].
In India, a study by Singh et al. reported that the most
common risk factor was presence of urinary catheter (63.2%),
mechanical ventilation (63.2%), peritoneal dialysis (63.2%),
followed by central line insertion (47.4%), diabetes mellitus
(26.3%) and use of corticosteroids (21.1%) of patients with
fungal colonization of ICU patients [14]. In another Indian study
by Jain et al., prolonged antibiotic therapy (100%), diabetes
mellitus (38.6%) and previous surgery (52.9%) were the
universal risk factors reported, where 100% of catheterized
ICUs patients had previous history of antibiotics. Antibiotics
increase the risk of colonization of Candida spp. by
suppressing endogenous ﬂora [15]. Likewise, Sahni et al.
reported that the antibiotics use, mechanical ventilation and
central catheters signiﬁcantly related to candidaemia [16]. High
rate of colonization has been reported in critically ill surgical
patients [13]. Urinary catheterization and broad-spectrum anti-
biotics use were the most common risk factors. On the other
hand, Harvey and Myers observed that the most common risk
factors in adult patients were central catheterization and blood
transfusion [17].
In this study, CG1 (patients with C. albicans colonization)
had risk factors of duration of stay > 1 week in ICU (36.8%) andimmunosuppressant (31.6%), and CG2 (patients with NAC
colonization) had risk factors of multiple organ system
involvement (35.5%), indwelling devices (96.8%), prolonged
antibiotic therapy (77.4%), duration of stay > 1 week (45.2%),
use of immunosuppressant (38.7%) and diabetes mellitus
(35.5%) which were signiﬁcantly higher and statistically sig-
niﬁcant (P < 0.05) than the control group. The number of pa-
tients with central line insertion (81.3%) and urinary catheter
(85.7%) were signiﬁcantly more in fungal infection group,
whereas those with peritoneal dialysis (63.2%) were signiﬁ-
cantly more in fungal colonization group. However, there was
no signiﬁcant difference in the mean duration of presence of
these risk factors in both the groups [14].
We observed a predominance of NAC species (63.3%)
however C. albicans was the most frequently isolated species
(36.7%). This is also consistent with the emergence of pre-
dominance of NAC species worldwide [14]. The preponderance
of C. tropicalis in our study, is consistent with a prospective
study by Chakrabarti et al., where C. tropicalis was the most
common (42.1%) yeast isolated [18].
We report a lower rate ofC. glabrata (10%) andC. parapsilosis
(6.7%) almost similar to a study among adult diabetes mellitus
patients byAl-Attas and Amro, in which they also reported a lower
rate of C. glabrata (11.1%) and C. parapsilosis (6.7%) [19].
Traditionally, C. tropicalis has been the second and C. glabrata
the third or fourth most common Candida species isolated [20].
Our study clearly shows that C. krusei (3.3%) and C. kefyr
(2.2%) are relatively rare as seen in rest of India [18,21,22]. In last
few decades, there have been numerous reports documenting the
rare isolation of C. kefyr and C. krusei [21–24].
In this study, Candida colonization rate was 50%, which is
similar to the colonization rate of 51% found in a previous in-
ternational multicentric study from 75 countries [25]. Candida
colonization rate due to NAC isolates (63.3%) was higher than
C. albicans isolates (36.7%). In our study, urinary tract
Candida colonization was the most common.
In our study, highest rate of Candida colonization was seen
in 41–50 years (75.00%) followed by 0–10 years (66.67%), > 60
years (55.60%), could be due to lowered host defenses at ex-
tremes of age. This ﬁnding is also supported by many other
researchers'. Prolonged antibiotic use increases the risk of
colonization of Candida species by suppressing the endogenous
ﬂora [15]. Higher rate of Candida colonization in 0–9 years could
be understood as they are more susceptible to infections due to
various reasons including weak immune systems and in the > 60
years age group this could correlate with prevalence of
debilitating conditions, decreased immune status and aging [26].
The most common site of Candida isolation was urine
(43.3%), followed by tracheal aspirate (31.1%), urinary catheter
(12.2%), endotracheal tube (7.8%), abdominal drains (3.3%) and
sputum (2.2%). Singh et al., reported that in medical and sur-
gical critical care section patients, the most common site or
specimen of fungus isolation in patients was also urine (74.7%),
followed by blood (20.8%) [14]. In a study by Jain et al.,
C. tropicalis was predominant in catheterized ICU patients [15]
similar to our study where C. tropicalis was most common
isolate from catheterized and endotracheal patients.
In this study, C. albicans was most commonly isolated from
urine and tracheal samples. Most observational studies of can-
diduria have reported C. albicans to be the predominant species
isolated [27]. However, Paul et al., reported C. tropicalis as the
most prevalent NAC species causing candiduria [28].
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species was common, occurring at least once in 73% of patients,
a ﬁgure not dissimilar to that found in prior studies [12]. As the
length of stay in ICUs and the frequency of invasive procedures
increases, the incidence of Candida colonization and Candida
infection increases [13]. Most patients suffer no ill effects due
to Candida colonization because of its low-level virulence;
however, in some patients with suppressed defenses, the or-
ganisms invade and cause illness [13]. Stamos and Rowley [29]
reported that Candida colonization was observed after 7 days
of hospitalization, which is similar to our results.
In our study 37.8% Candida isolates demonstrated resistance
to ﬂuconazole, concordant to a study by Deorukhkar et al. [27].
In our study, the resistance rate for ﬂuconazole (37.8%) was
more compared to amphotericin B (7.8%). In the present
study, C. tropicalis isolates were found to be more resistant to
ﬂuconazole (38.5%). The increase in the rate of ﬂuconazole
resistance in C. tropicalis is of concern because this species is
one of the most commonly isolated NAC species and
ﬂuconazole is the most common antifungal agent used for the
treatment of various types of candidiasis [27]. In this study,
C. albicans (36.4%) isolates was also found to be resistant to
ﬂuconazole, compared to the different resistance rates reported
in other studies (10.5–21%) [30].
A hundred percent resistance was reported for C. krusei, with
its greatest potential to acquire resistance to ﬂuconazole because
of its intrinsic resistance toward azoles and poor susceptibility to
all other antifungals, including amphotericin B [31,32]. Also, the
resistance of C. glabrata to ﬂuconazole was consistently higher
(16.7%) with increased resistance (19.2%) reported by Bassetti
et al. [20]. A reduced antifungal susceptibility in NAC species
and a correlation with routine ﬂuconazole prophylactic use has
been suggested [20]. Extensive ﬂuconazole use is one of the
possible causes, for the increased resistance to the drug as
well as for the progressive substitution of albicans species
with non-albicans drug resistant strains as principal etiologic
agent of infection [33]. The sensitivity pattern of Candida
species as revealed in this study shows that amphotericin B to
be suitable drug for empirical therapy unlike ﬂuconazole with
a high resistance in Candida species [30].
The outcomes of our study, highlight the predominance of
NAC species colonization in ICU patients similar to the trends in
the western countries, a cause of concern in our country as re-
ported by other workers too [14]. The major risk factors were use
of indwelling devices, prolonged antibiotic therapy and surgery.
The increase in resistance being recorded to ﬂuconazole has a
major bearing on the morbidity and management of these
patients and needs to be further worked upon. Identiﬁcation and
antifungal susceptibility of Candida isolates from ICU patients
will help in building a data center of the prevalent Candida
species along with their antifungal resistance proﬁle and will go
a long way in the management of these serious patients.
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